PlexBio Co., Ltd. (6572.TWO)
- Previous Close
10.50 - Open
10.35 - Bid 10.80 x --
- Ask 11.00 x --
- Day's Range
10.35 - 11.50 - 52 Week Range
8.57 - 14.30 - Volume
192,147 - Avg. Volume
48,476 - Market Cap (intraday)
1.14B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.59 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
www.plexbio.comRecent News: 6572.TWO
View MorePerformance Overview: 6572.TWO
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6572.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6572.TWO
View MoreValuation Measures
Market Cap
1.09B
Enterprise Value
678.46M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.57
Price/Book (mrq)
2.91
Enterprise Value/Revenue
5.30
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-48.13%
Return on Assets (ttm)
-9.13%
Return on Equity (ttm)
-15.43%
Revenue (ttm)
128.06M
Net Income Avi to Common (ttm)
-61.63M
Diluted EPS (ttm)
-0.59
Balance Sheet and Cash Flow
Total Cash (mrq)
415.53M
Total Debt/Equity (mrq)
1.51%
Levered Free Cash Flow (ttm)
16.78M